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 Abstract 
Borna disease virus (BDV) is the causative agent of a neurological disorder in mammals and 
ostriches called Borna disease. BDV is also of interest as infective agent in humans with 
psychiatric diseases, such as mood disorders and schizophrenia, as well as in experimental 
models of these diseases. In Sweden, the progressive and mostly fatal neurological disorder 
among domestic cats, known as staggering disease or feline Borna disease, is caused by 
BDV. Except for cats, natural BDV infection has also been described in horses and a free-
ranging lynx in Sweden. Major clinical signs of staggering disease are staggering 
movement, alteration in behaviour, lumbosacral pain and inability to retract the claws. 
Today staggering disease is clinically suspected by excluding other reasons for clinical 
signs and the diagnosis is further established by examining the central nervous system 
histopathologically at autopsy. The diagnosis is finally confirmed by immunohisto-
chemistry. In order to get a better clinical diagnostic tool, a duplex real-time polymerase 
chain reaction (PCR) assay was developed. This assay has been proven positive with 
different strains of BDV in infected cell lines and brain tissue samples of experimentally 
infected cats. Further evaluation of the new assay has to be done, such as testing the 
sensitivity and finding the best type of sample from the living patient. When the diagnostic 
method is finally evaluated it will also be essential in the evaluation of new therapies, as 
well as in epidemiological studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sammanfattning 
Bornavirus (Borna disease virus, BDV) orsakar en neurologisk sjukdom, som kallas 
bornasjuka, hos flera däggdjur och struts. BDV har också visat sig vara intressant vid vissa 
psykiatriska sjukdomar hos människa, såsom depression och schizofreni, eftersom virus och 
antikroppar har påvisats hos patienter med sådana sjukdomar. Dessutom är experimentellt 
infekterade försöksdjur intressanta som modeller för psykiatrisk sjukdom. I Sverige 
förekommer en progressiv och ofta fatal neurologisk sjukdom hos katt, som kallas för 
vingelsjuka. Denna orsakas av BDV. Förutom hos katter har naturlig bornavirusinfektion i 
Sverige även beskrivits hos hästar och ett lodjur med neurologiska symtom. Framstående 
symtom på vingelsjuka är vinglig gång (bakbensataxi), beteendeförändringar, smärta från 
länd- och korsrygg samt oförmåga att dra in klorna, framför allt på bakbenen. Idag 
misstänks den kliniska diagnosen genom att utesluta övriga orsaker till symtom och 
diagnosen kan inte styrkas förrän vid en histopatologisk undersökning av hjärna, 
hjärnhinnor och ryggmärg efter obduktion. Diagnos kan slutligen fastställas vid 
immunhistokemi. För att få en möjlighet att ställa diagnos hos den levande katten har en 
realtids-PCR utvecklats. Denna har visat sig vara positiv vid ett test där olika virusstammar 
användes, både från infekterade celler och hjärnvävnad från experimentellt infekterade 
katter. Fortfarande behöver flera studier göras innan den kan användas kliniskt. 
Känsligheten ska testas och även vilket typ av provmaterial från den levande patienten som 
innehåller mycket virus. När diagnostiken är utprovad kommer den även vara ett användbart 
verktyg vid utveckling av nya behandlingar och vidare studier av sjukdomens epidemiologi. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Contents 
Introduction 9 
Borna disease – historical background 10 
Borna disease virus – virus biology and genetic properties 10 
Borna disease in Sweden – not only staggering disease in cats 11 
Epidemiology – search for a possible natural reservoir 12 
Diagnostic methods – advantages and disadvantages 12 
Materials and methods 14 
Cells 14 
Animals 14 
RNA-preparation 14 
Nested RT-PCR assay 15 
Real-time PCR assay 15 
Optimisation of real-time PCR assays 16 
Results 16 
Nested RT-PCR assay 16 
Optimisation of real-time PCR assays 17 
Specificity test 20 
Discussion 21 
Acknowledgments 24 
References 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9
Development of a real-time PCR for in vivo 
diagnosis of feline Borna disease 
 
Introduction 
Feline Borna disease (BD), or “staggering disease” (SD), is a neurological disorder 
in cats, mainly characterised by a staggering movement (hind-leg ataxia), 
behavioural changes, lumbosacral pain and an inability to retract the claws 
(Lundgren 1992). The disease is clinically suspected by excluding other reasons 
for clinical signs. Histopathological examination of the brain, meninges and spinal 
cord will further strengthen the diagnosis, and finally it is confirmed by 
immunohistochemistry (figure 1). Serological tests have been used, but not all 
BDV-infected cats are seropositive (Nakamura et al. 1996, Johansson, Berg & 
Berg 2002). Furthermore, antibodies have also been found in healthy cats (Nishino 
et al. 1999).  
 
 The lack of a good diagnostic tool for the living cat is a problem for the clinician 
and the owner but also for the authorities, since the clinical pattern is similar to 
feline spongiform encephalopathy (FSE), a disease regulated by the law (SFS 
1999:657, SJVFS 2002:97). The possibility to make an in vivo diagnosis of BD 
will also be a breakthrough for the evaluation of therapies, as well as 
epidemiological studies.  
 
 The aim of this study is to develop a duplex real-time polymerase chain reaction 
(PCR) assay for the diagnosis of feline BD in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Perivascular, mononuclear cell infiltrate in the mesencephalon of a cat with 
staggering disease. Scattered mononuclear cells and neurons contain BDV p40 protein 
(brown staining). Polyclonal anti-p40 rabbit serum, diluted 1:10000, ABC detection system. 
X200. 
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Borna disease – historical background 
The neurological disorder, known as Borna disease, has been described in German 
horses for several hundred years. In the late 19th century a major epidemic 
outbreak among military horses occurred in the city of Borna, nearby Leipzig in 
southeastern Germany, thereby the name of the disease. In the 1920s the viral 
etiology was shown and a vaccination program started in the endemic parts of 
Germany, although with no or little success (reviewed in Dürrwald & Ludwig 
1997, Ludwig & Bode 2000).  
 
 For a long time Borna disease was thought to be endemic in horses and sheep only 
in certain parts of central Europe, but virus and BDV-specific antibodies have now 
been found all over the world. The host range has also been widened and now 
natural BDV infection has been found in horses, sheep, rabbits, cattle, cats, dogs, 
ostriches, lynx and foxes, as well as humans (reviewed in Ludwig & Bode 2000, 
Dauphin et al. 2002).  In humans, BDV antibodies and antigen have been found in 
patients with psychiatric diseases, such as mood disorders and schizophrenia, 
although the significance of these data is under debate (reviewed in Carbone 
2001). 
 
Borna disease virus – virus biology and genetic properties 
Borna disease virus (BDV) is an enveloped, negative, non-segmented, single-
stranded RNA virus (Briese et al. 1992). It belongs to the order of 
Mononegavirales and due to its unique properties it is the sole member of the 
Bornaviridae family. The members of the order of Mononegavirales typically have 
5-10 genes encoding for the nucleoprotein (N), phosphoprotein (P), matrix protein 
(M), attachment or surface glycoprotein (G) and the polymerase protein (L). The 
transcription is initiated by a viral RNA-dependent RNA polymerase (Pringle 
1997). 
 
 The genome of BDV is about 8900 nucleotides and consists of six major open-
reading frames (ORFs). These encodes for six polypeptides called p40, p24, p10, 
p16, p56 and p180, due to their molecular weight in kilodalton (kDa). The 
polypeptide p40 corresponds to the viral nucleoprotein (N), p24 to the 
phosphoprotein (P) and p16 to the matrix protein (M), whereas p56 is thought to 
correspond to the surface glycoprotein (G) and p180 to the L polymerase protein. 
The function of the p10 polypeptide is unknown and is sometimes referred to as 
the X protein (Tomonaga, Kobayashi & Ikuta 2002). 
 
 BDV seems to be a conserved virus, since the different strains are genetically very 
similar. The two classical laboratory strains are strain V and He/80, both derived 
from horses. Some of the human strains, as well as other animal strains, show 
identical or almost identical genome sequences. Therefore, several scientists argue 
that the prevalence of BDV throughout the world is due to the limitation of the 
methods or contamination. A new variant of BDV was found in Austria (No/98) 
that showed more than 15% genetic variation from other strains (Nowotny et al. 
2000). 
 
 BDV has a strict neurotropism, at least in immunocompetent animals, and the 
replication takes place in the nucleus of infected cells (Morales et al. 1988, Briese 
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et al. 1992). A possible entry of infection is by the olfactory receptor cells in the 
olfactory epithelium and then an axonal transport of virus to the olfactory bulb 
takes place. From the neurons of the olfactory bulb, virus infects other parts of the 
brain via synapses and dendrites (Morales et al. 1988). In persistently infected 
animals, virus is found in almost all organs and infectious virus is also found in the 
urine (Morales et al. 1988, Sauder & Staeheli 2003). This is probably due to an 
axonal transport of virus to the urogenital tract (Morales et al. 1988). 
  
Borna disease in Sweden – not only staggering disease in cats 
The progressive, mostly fatal, neurological disorder, known as staggering disease 
(SD), was described in Sweden for the first time in 1974 (Kronevi et al. 1974). 
Histopathologically, SD is characterised by a non-suppurative inflammation in the 
brain, meninges and spinal cord, thereby indicating a viral disease. It was not until 
the 1990s Borna disease virus (BDV) could be determined as the etiological agent. 
This was shown in several studies, both by serological and molecular biological 
methods, as well as in experimental infections with BDV strain V and a feline 
isolate from a naturally infected cat (Lundgren & Ludwig 1993, Lundgren et al. 
1995a, Lundgren et al. 1995b, Lundgren et al. 1997). 
 
 In Sweden, feline Borna disease seems to be endemic in areas around the cities of 
Stockholm and Uppsala (Mälardalen and Uppland) (Lundgren 1992). Feline Borna 
disease has also been reported in Austria, Switzerland, United Kingdom, Japan and 
Germany, although BDV-specific antibodies have been found even in other 
countries (Nowotny & Weissenböck 1995, Bornand et al. 1998, Reeves et al. 
1998, Nakamura et al. 1999, Huebner et al. 2001, Helps et al. 2001, Horii et al. 
2001). More recently, Borna disease has also been described in horses and a free-
ranging lynx in Sweden (Berg, Skidell & Berg 1998, Berg, Dörries & Berg 1999, 
Degiorgis et al. 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cat with staggering disease, paralysed in its hind-legs. 
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Epidemiology – search for a possible natural reservoir 
Most of the cats with feline BD start to show clinical signs (mainly staggering 
movement (hind-leg ataxia), behavioural changes, lumbosacral pain and an 
inability to retract the claws, see figure 2) from December to July (Lundgren 1992, 
Hultin-Jäderlund 2003). Similar seasonal patterns have been seen in naturally 
infected horses and sheep (Dürrwald & Ludwig 1997, Vahlenkamp et al. 2002). 
This, together with the geographical localizations, indicates some kind of natural 
reservoir. Furthermore, feline BD is mostly seen in cats with access to rural and/or 
woodland environment, as well as in cats that are hunting mice (Berg et al. 1998). 
 
 Several possible reservoirs have been suggested, among them rodents, birds and 
ticks. However, serological surveys of wild rodents in Asia have not shown any 
signs of BDV infection (Tsujimura et al. 1999, Hagiwara et al. 2001). A Swedish 
BDV infected lynx was infested with ticks, but none of the investigated ticks were 
BDV-positive (Degiorgis et al. 2000). The only suggested reservoir shown to be 
positive for BDV has been wild birds. In 2001, faecal samples from two mallards 
and one jackdaw in Uppsala were reported to contain BDV-specific RNA (Berg et 
al. 2001). However, these findings do not exclude other natural reservoirs. 
 
 The interesting finding that experimentally infected neonatal rats excrete 
infectious BDV in their urine has raised a hypothesis of the transmission of BDV 
among horses and sheep (Morales et al. 1988). Wild rodents persistently infected 
with BDV may possibly contaminate hay or other feed. When horses and sheep 
consume it, virus can be up-taken by the neurons in the nasal or pharyngeal 
mucosa (Staeheli et al. 2000). This hypothesis was tested experimentally by 
introducing naive rats in cages with persistently infected rats. The results show that 
fresh urine was probably the way of transmission between the two groups of rats. 
BDV-infected cells were mainly found in the olfactory pathways, indicating uptake 
of virus in the olfactory receptor cells (Sauder & Staeheli 2003). It has also been 
shown that experimental vertical transmission exists in pregnant mice (Okamoto et 
al. 2003). Therefore, the natural reservoir could be a persistently BDV-infected 
rodent population. 
 
 In cats, infected rodents and/or birds could be a possible way of infection by prey 
or by contaminating the surroundings. Ticks are still interesting as a reservoir, 
since the areas where feline BD are found in Sweden, also are known for ticks 
residing. 
 
Diagnostic methods – advantages and disadvantages 
As discussed in the general introduction, today the only way to make a confident 
diagnosis is to perform an autopsy and a histopathological examination including 
immunohistochemistry. Serology is not a good method, because of the high 
amount of false positive and false negative animals (Nakamura et al. 1996, 
Nishino et al. 1999, Johansson, Berg & Berg 2002). 
 
 Conventional nested reverse transcriptase polymerase chain reaction (nested RT-
PCR) is a very sensitive method, but it is also very sensitive to contamination. This 
is because of the handling of the samples after one round of amplification, when 
PCR products are easily transferred to other (negative) samples. The way of 
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detecting PCR products by gel electrophoresis is also time-consuming and only 
semi-quantitative. The further developed method of real-time PCR do not have any 
post-PCR handling and due to that the risk of contamination is lowered, as well as 
the time consumed. The number of templates initially present in the sample is also 
possible to quantify. 
 
 Simplified, one can say that the real-time PCR machine consists of one rapid 
thermal cycler unit and one laser spectrophotometer unit. The fluorescence 
intensity increases for every cycle of amplification, as the number of templates 
increases. There are three different ways of getting the fluorescence: a) SYBR-
green, b) molecular beacons and c) Taqman probes. All of them use different kind 
of fluorescent molecules binding to DNA. 
 
 SYBR-green binds into the minor grooves of double-stranded DNA, thereby 
increasing the intensity of fluorescence. After every cycle of amplification the 
template amplified will increase and so will the fluorescent emission. The SYBR-
green will bind to any double-stranded DNA, and in that sense it is unspecific 
(Applied Biosystems 2003). 
 
 Molecular beacons are hair-pinned oligonucleotides with a fluorophore and a 
quencher close together. When the oligonucleotide and its specific target DNA 
have hybridised, the fluorophore and quencher separate from each other. The 
fluorophore then starts to fluoresce (Vet, van der Rijt & Blom 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The principle of Taqman. During the elongation step the Taq polymerase cleaves 
the probe, and the reporter and quencher dyes separate. Now the reporter can emit its 
fluorescence.  
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Taqman probes are oligonucleotides with a high-energetic reporter dye at its 5’ end 
and a low-energetic quencher dye at its 3’ end (figure 3). As long as the probe is 
intact, the quencher suppresses the reporter. During the elongation step, the Taq 
(Thermus aquaticus) polymerase removes nucleotides in front of it by its 5’–3’ 
endonuclease activity. When the probe is cleaved, the distance between the 
reporter and the quencher increases. The quencher is then no longer able to 
suppress the reporter and a fluorescent emission appears (Mackay, Arden & 
Nitsche 2002, Applied Biosystems 2003). 
 
 In this study, Taqman probes with two different kinds of reporter dyes at different 
wavelengths (FAM and ROX) and a so-called black hole quencher, which does not 
give any fluorescence background, were used. 
 
Materials and methods 
Cells 
During the optimisation, with respect to primer, manganese acetate and probe 
concentration, of the real-time PCR assays, C6 (rat glioma) cells infected with 
BDV He/80 (Carbone et al. 1993) were used. The cells were diluted in a tenfold 
dilution series. In the specificity test, Vero monkey cells infected with BDV No/98 
(Nowotny et al. 2000) also were used. 
 
Animals  
In the specificity test, brain tissue samples from cats experimentally infected with 
BDV strain V and a feline isolate (Lundgren et al. 1997), as well as from some 
naturally infected cats (cats with staggering disease) were used. RNA from five 
horses with neurological disorder (Berg, Dörries & Berg 1999) and brain tissue 
from a BDV-infected free-ranging lynx (Degiorgis et al. 2000) were also used 
during this test. 
 
RNA-preparation 
Total RNA from cultured cells and brain tissue samples was extracted with Trizol 
and Trizol LS reagents (Invitrogen Life Technologies). The manufacturer’s 
protocol was slightly modified. Briefly, RNA preparation was done by adding 1 ml 
of Trizol or 0.75 ml of Trizol LS per 50-100 mg of tissue or 0.25 ml of cultured 
cells. The tissue was homogenised manually with a single use mortar. After an 
incubation of five minutes at room temperature, 0.2 ml of chloroform was added 
per 1 ml Trizol/ 0.75 ml of Trizol LS initially used. The samples were then 
incubated another 2-3 minutes at room temperature before they were centrifuged at 
<12000g at 2-8°C. The aqueous phase was transferred to a fresh tube and the RNA 
was precipitated with 0.5 ml isopropyl alcohol per 1 ml Trizol/ 0.75 ml of Trizol 
LS initially used. After an incubation of 10 minutes at room temperature the 
samples were centrifuged at <12000g at 2-8°C. The RNA was then washed once 
with 1 ml of 75% ethanol and then redissolved in RNAse-free water. The 
concentration and the purity were then estimated by spectrophotometry. 
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Nested RT-PCR assay 
The RT reaction was performed in a final volume of 40 µl containing 2.5 µg of 
total RNA. The RNA was mixed with 1.06 µg of cDNA primer and 1 mM of each 
dNTP and incubated at 65°C for 5 minutes. Then 1x first strand buffer, 10 mM 
DTT and 80 U of RNAseOUT (Invitrogen Life Technologies) were added and 
incubated at 42°C for 2 minutes. After adding 400 U of the reverse transcriptase, 
Superscript II (Invitrogen Life Technologies), the RT reaction was performed at 
42°C for 50 minutes. To inactivate the enzyme the samples were incubated at 70°C 
for 15 minutes. 
 
 First PCR amplification was performed with 1 µl of cDNA from the RT reaction 
in a final volume of 25 µl. The reaction mix consisted of 1x PCR buffer with 
ammonium sulphate, 1x magnesium chloride, 10 pmol of each primer and 2.5 U of 
Taq polymerase (Invitrogen Life Technologies). The samples were processed 
through 40 cycles of 30 seconds at 95°C, 1 minute at 55°C and 1.5 minute at 72°C, 
with a final extension of 5 minutes at 72°C. 
 
 Nested PCR amplification was performed at the same conditions as first PCR, 
although the samples were processed through 35 cycles of 30 seconds at 95°C, 30 
seconds at 60°C and 1.5 minute at 72°C. For the nested PCR amplification 1 µl of 
first PCR product was used in a final volume of 25 µl. 
 
 Gel electrophoresis was performed with a 1.5% agarose gel with TAE-buffer by 
transferring 10 µl of each nested PCR product with 2 µl of loading dye. The gel 
was stained with ethidium bromide after a run of about 60-90 minutes at 150 V. 
 
Real-time PCR assay 
The probes used were designed by aligning (Multalin version 5.4.1) the sequences 
of the P and L genes of the strains He/80 (GenBank accession number AJ311522) 
and No/98 (GenBank accession number AJ311524) and by using the program 
Beacon Designer 2.1. Both of the probes had no mismatches for these strains. The 
P gene probe (5’-FAM-CAGCGAACCGGAAGGGAGCAGCTATC-BHQ-3’) 
was 26 nucleotides in length and the L gene probe (5’-ROX-
AGGGCAAGTGGGCATGATATTATGGAGCAG-BHQ-3’) was 30 nucleotides 
in length.  
 
 The primers were designed in the same way as the probes. The P gene sense 
primer (5’-GAACCCCTCCATGATCTCAGAY-3’) had one mismatch and the 
anti-sense primer (5’-CTCYGTCACTAGCTTCTTGATRAG-3’) had two. The L 
gene primers were designed as one pair of non-degenerated primers, identical to 
He/80, and one pair of degenerated primers, as a consensus of He/80 and No/98. 
The L gene sense non-degenerated primer had following sequence, 5’-
GGATTCTCATTGGCAAGTCATTCT-3’, whereas the anti-sense non-
degenerated primer had 5’-CCTCTCCAAGTTAGCCCATGT-3’. The L gene 
sense degenerated primer (5’-GRATTCTYATTGGCAAGTCRTTCT-3’) had 
three mismatches and the anti-sense degenerated primer (5’-
CCKCTCMAYGTTWGCCCAYGT-3’) had five. 
 
 16
 Primers and probes were ordered from Biosearch Technologies Inc., CA, USA. 
The length of the PCR products in these two systems is 88 and 89 base pairs 
respectively. 
 
 The real-time PCR assay was prepared with special precaution for contaminations, 
as previously described (Belák & Thorén 2001). This was done by preparing the 
reaction master mix in a separate laboratory from the adding of RNA. 
Furthermore, when RNA was added, tube holders and openers were used to avoid 
cross contamination. 
 
 The chemicals used in the master mix, except for primers and probe, was rTth 
(Thermus thermophilus) DNA polymerase (2.5 U/µl), 5X EZ buffer (250 mM 
bicine, 575 mM potassium acetate, 40% (w/v) glycerol, pH 8.2) and 25 mM 
manganese acetate (all three, Applied Biosystems), 10 mM of each dNTP, 1 mg/ml 
of bovine serum albumin (BSA) and DMPC-treated water to a total volume of 25 
µl.  
 
 The rTth DNA polymerase has the ability to act as both reverse transcriptase and 
DNA polymerase under the right conditions, thereby allowing the use of the same 
enzyme in the reverse transcriptase (RT) reaction as in the PCR reaction, without 
changing reaction conditions. The RT reaction was performed with an initial 
incubation at 42°C for 5 minutes, followed by another incubation at 60°C for 30 
minutes. After a third incubation at 95°C for 3 minutes the samples were processed 
through 40 cycles of 30 seconds at 94°C, 30 seconds at 50°C and 45 seconds at 
72°C. The data were then analysed and presented with Sequence Detection 
Systems 1.9 (Applied Biosystems). The real-time PCR machine in use was the ABI 
PRISM 7700 Sequence Detector. 
 
Optimisation of real-time PCR assays 
The real-time PCR assays were optimised with respect to primer, manganese 
acetate and probe concentration according to standard procedures at the 
Department of Virology, National Veterinary Institute, Uppsala, Sweden. To 
evaluate which set of primer concentrations that were best, nine different 
concentrations of forward/reverse primers were used in duplicates (50/50, 50/300, 
50/900, 300/50, 300/300, 300/900, 900/50, 900/300 and 900/900, all 
concentrations in nM). Seven different concentrations of manganese acetate were 
used in the optimisation, ranging from 1.5 to 4.5 mM. All concentrations were run 
in duplicates. For the probe titration, four different concentrations (100, 200, 300 
and 400 nM) were used in duplicates. The optimisation was performed for each 
primer pair (P gene, L gene non-degenerated and degenerated).  
 
Results 
Nested RT-PCR assay 
In order to test the RNA quality after preparation, some of the samples were tested 
in nested RT-PCR assay with β-actin primers (figure 4). This gene is expressed in 
all cells and if the RNA is of bad quality, no or weak PCR product is seen. At the 
same time, the samples were tested if they were BDV positive using BDV-p23/P 
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and BDV-p40/N primers. The samples were then used in the real-time PCR assay. 
Samples that were BDV positive in the nested RT-PCR assay were also positive in 
the real-time PCR assay. However, the RNA from natural infected horses and cats, 
that earlier had been positive with conventional RT-PCR (Berg, Dörries & Berg 
1999, M Berg unpublished results), showed to be negative with real-time PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Gel electrophoresis of nested RT-PCR showing C6 (rat glioma) cells infected with 
BDV He/80, brain tissue from a cat experimentally infected with strain V and brain tissue 
from an uninfected cat. p23 = BDV-p23/P, p40 = BDV-p40/N, actin = β-actin.  
M = molecular weight marker. 
 
 
Optimisation of real-time PCR assays 
 The optimisation resulted in a reaction protocol for each system (Table 1a and 1b). 
The L gene non-degenerated and degenerated primer systems resulted in the same 
protocol. Finally, reaction efficiency were calculated for each system by running a 
dilution series from 1:1 to 10-6 and then making a standard curve. The reaction 
efficiency, y-intercept and correlation co-efficiency are shown in table 2, where 
reaction efficiency is the number of copies amplified each cycle, y-intercept 
corresponds to the number of cycles required to amplify one unit of template to 
reach the fluorescence threshold and correlation co-efficiency is a measure of how 
well the data correlates to the given concentrations of the standard. 
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Table 1a. BDV p23/P-gene real-time PCR protocol. 
 
Reagents per reaction 1X (µl) Final conc. 
 
DMPC-H20 6  -   
5X EZ buffer 5  1X 
Mn(OAc)2 (25 mM) 2.5  2.5 mM 
4XdNTPs (10 mM) 1.25  0.5 mM 
BSA (1 mg/ml) 2  0.08 mg/ml 
p23/P-probe (10 µM) 0.75  0.3 µM 
rTth polymerase (2.5 U/µl) 1  0.1 U/µl 
F-primer p23/P (10 µM) 2.25  0.9 µM 
R-primer p23/P (10 µM) 2.25  0.9 µM  
 RNA: 2 µl 
 Total: 25 µl 
 
Table 1b. BDV L-gene (non-degenerated and degenerated primers) real-time PCR protocol. 
 
Reagents per reaction 1X (µl)  Final conc. 
 
DMPC-H20 7.25  -   
5X EZ buffer 5  1X 
Mn(OAc)2 (25 mM) 2.5  2.5 mM 
4XdNTPs (10 mM) 1.25  0.5 mM 
BSA (1 mg/ml) 2  0.08 mg/ml 
L-gene probe (10 µM) 1  0.4 µM 
RTth-polymerase (2.5 U/µl) 1  0.1 U/µl 
F-primer L-gene (10 µM) 0.75  0.3 µM 
R-primer L-gene (10 µM) 2.25  0.9 µM 
 RNA:  2 µl 
 Total: 25 µl 
 
 Table 1c. BDV duplex real-time PCR protocol. 
 
Reagents per reaction 1X (µl)  Final conc. 
 
DMPC-H20 2  -   
5X EZ buffer 5  1X 
Mn(OAc)2 (25 mM) 2.5  2.5 mM 
4XdNTPs (10 mM) 1.25  0.5 mM 
BSA (1 mg/ml) 2  0.08 mg/ml 
p23/P-probe (10 µM) 0.75  0.3 µM 
L-gene probe (10 µM) 1  0.4 µM 
RTth-polymerase (2.5 U/µl) 1  0.1 U/µl 
F-primer p23/P (10 µM) 2.25  0.9 µM 
R-primer p23/P (10 µM) 2.25  0.9 µM 
F-primer L-gene (10 µM) 0.75  0.3 µM 
R-primer L-gene (10 µM) 2.25  0.9 µM 
 RNA: 2 µl 
 Total: 25 µl 
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Table 2. Reaction efficiency (E) in percent, y-coefficient (Y) and correlation co-efficiency 
(C) are shown for each real-time PCR assay. 
 
Assay E Y C 
 
p23/P gene 60 33.696 0.964 
L-gene non-degenerated 82 35.034 0.963 
L-gene degenerated 57 35.662 0.958 
 
The first run with duplex real-time PCR, that is both the P and L gene systems in 
the same tube, was run with the individual system protocols put together. Only 
slight differences could be seen between the duplex and simplex systems and the 
duplex system seemed to be better than the simplex (Figure 5 a & b). Therefore, 
the duplex real-time PCR reaction protocol resulted in adding the two simplex 
protocols together (Table 1c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 a). Comparison between duplex and simplex real-time PCR assay (p23/P-gene). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 b). Comparison between duplex and simplex real-time PCR assay (L-gene 
degenerated primers). 
 20
 
Specificity test 
To see the specificity of the real-time PCR assay, some different strains were used 
in a specificity test. The system was designed for He/80, but also for No/98, a 
strain that differs quite a lot genetically, as discussed in the introduction. The 
strains used for the specificity test were He/80, No/98, strain V and a feline isolate 
from a naturally infected cat, as well as samples from some naturally infected 
horses, cats and a lynx. Those positive were He/80, No/98, strain V and in some 
extent perhaps also the feline isolate, as shown in figure 6 a-c, but further 
experiments have to be performed to confirm the last observation. 
 
 
 
 
 
 
 
 
 
 
Figure 6 a). BDV specificity test, duplex and simplex real-time PCR assay (p23/P). He/80 = 
C6 BDV He/80 infected cells, strain V = experimentally infected cat (brain tissue),  
No/98 = Vero monkey cells infected with BDV No/98. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 b). BDV specificity test, duplex and simplex real-time PCR assay (L-gene non-
degenerated primers). See figure 6 a) for explanations. 
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Figure 6 c). BDV specificity test, duplex and simplex real-time PCR assay (L-gene 
degenerated primers). Feline isolate = brain tissue from cat experimentally infected with a 
feline isolate from cat with staggering disease. See also figure 6 a) for explanations. 
 
 
Discussion 
Today there is no way to make a confident diagnosis of feline Borna 
disease/staggering disease in the living cat. This is of course a problem for owners 
and practitioners, but also for the evaluation of relevant therapies. Results of a 
clinical and neurological examination are not specific, and could mimic the 
findings in other central nervous system diseases, such as feline spongiform 
encephalopathy (FSE). Serology is not reliable, as discussed earlier, and neither 
haematology nor serum chemistry is diagnostic either. Recently, a study showed 
that an enzyme immune assay directed towards BDV-specific circulating immune 
complexes (antibodies bound to antigen) was a better method than other 
serological assays. The authors suggest that three different immune assays towards 
circulating immune complexes, plasma antigen and antibodies would be a 
powerful diagnostic tool. However, these have only been used for humans and 
horses, but could in principle be adapted for cats (Bode et al. 2001). The presence 
of antibodies in cerebrospinal fluid is probably more adequate than in blood, but 
such a sample is relatively difficult and risky to obtain and the cat has to be 
anaesthetised. Therefore, a simply taken sample, like blood or conjunctival fluid, 
would be convenient for subsequent search for viral RNA. A modern variant of 
RNA detection is the real-time PCR assay. It is a sensitive method and not as time-
consuming as nested RT-PCR, where the detection of PCR products is done by gel 
electrophoresis. Real-time PCR also has the advantage of not including any post-
PCR handling, and therefore the risk of cross contamination is decreased. 
 
 In order to develop such a diagnostic method, certain criteria have to be fulfilled. 
It has to be specific and sensitive, which means that it has to detect different strains 
of the virus, but no other virus, and also detect the virus of interest in low 
concentration. 
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Firstly, probes and primers were designed by aligning two different BDV strains, 
He/80 and No/98, to find the most homologous regions. Most strains are 
genetically very similar to the standard laboratory strains He/80 and strain V, both 
derived from horses. However, No/98 is the strain with most variations genetically, 
compared to other strains. Because of the difficulty to find homologous regions in 
the L gene that were sufficiently long for a probe and two primers to fit, two pairs 
of primers were designed. One pair was non-degenerated and homologous to 
He/80. The other pair was degenerated and homologous to both He/80 and No/98. 
Two different gene systems (L and p23/P genes) were used to decrease the risk of 
contamination. The probability for contaminating the same sample with both genes 
or PCR products of those genes should be quite low, especially since only the 
p23/P and p40/N genes have been used in conventional RT-PCR at this laboratory. 
 
 The two systems were then individually optimised with respect to primer, 
manganese acetate and probe concentrations, according to standard protocols at the 
Department of Virology, Swedish National Veterinary Institute, Uppsala. These 
two systems were put together in a duplex assay, by just adding the two individual 
protocols. The duplex and simplex assays seemed to work equally well when 
compared. 
 
 In order to test the specificity of this new real-time PCR assay, some different 
strains were used. The strain used in the optimisation was He/80, and apart from 
that strain, No/98, strain V and a feline isolate from a naturally infected cat were 
used, as well as material from some naturally infected horses, other cats and a 
lynx. The He/80 and strain V strains were positive in all systems used. The No/98 
were positive in all systems except for the non-degenerated L gene system. 
Probably this is due to the number of mismatches in the non-degenerated primers. 
The feline isolate seemed to be positive in the degenerated L gene system only. 
This has to be repeated in order to know whether or not it is a true result. The 
naturally infected horses, cats and lynx were all negative in this test, although they 
had been positive with conventional nested RT-PCR earlier. This was possibly 
because of degradation of RNA during storage, PCR inhibitors or low sensitivity 
of the real-time PCR assay. 
 
 One way to overcome the problems with not knowing the quality and quantity of 
RNA in the samples, and thereby not knowing if a negative sample is truly 
negative, is to add another system in the assay. A possible way is to use primers 
and probe for a feline ribosomal RNA (rRNA). This has been done in detection of 
Chlamydophila felis and feline herpesvirus by a multiplex real-time PCR (Helps et 
al. 2003). If the sample contains low amounts of feline cells, the amount of feline 
rRNA is low. The reason could be an incorrect technique of taking the sample and 
therefore the sample should be retaken. This approach is useful in a clinical 
diagnostic test and the test result will be easier to interpret for the clinician. 
 
 Next step in evaluating the new assay is to perform a sensitivity test. This will be 
done with known concentrations of templates of the PCR products, such as in vitro 
transcribed plasmid DNA. To be a useful diagnostic tool this assay has to detect 
even low concentrations of viral RNA. To see if the assay only detects the virus of 
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interest (BDV), samples known to be positive for other virusez of the same order 
(Mononegavirales), like canine distemper virus, will be tested. 
 
When the specificity and sensitivity of the assay are known, time has come to test 
the clinical samples. For this purpose, different types of material (conjunctival 
fluid, saliva, nasal fluid, blood, urine, faeces and cerebrospinal fluid) have been 
collected from cats with suspected feline BD or staggering disease at the 
Department of Small Animal Clinical Sciences, Swedish University of Agricultural 
Sciences, Uppsala. Most of them have also been autopsied and examined 
histopathologically, where the diagnosis has been confirmed. At autopsy, different 
parts of the brain and olfactory epithelium have been collected. Earlier studies 
have shown that nasal and conjunctival fluids, as well as saliva in seropositive 
horses contain BDV-specific RNA (Richt et al. 1993). This was also the case in 
naturally infected sheep (Vahlenkamp et al. 2002). The entry of infection is 
probably by the olfactory pathway, as discussed earlier. Possibly, the replication is 
initiated in the olfactory epithelium before virus is transmitted to the olfactory bulb 
and other parts of the brain. This could be a reason for finding viral RNA in nasal 
fluid. As discussed in the introduction, persistently infected rats shed infectious 
virus in their urine, probably due to a transport of virus via peripheral nerves to the 
urine bladder wall. However, if this also is the case in other infected animals, as 
the cat, is not known. 
 
 This study shows that a duplex real-time PCR assay works with different strains 
of BDV, not only with infected cell lines, but also with brain tissue samples. In the 
only previous study where real-time PCR assay has been used for BDV, it was 
used to quantify the number of BDV mRNAs present in different parts of the brain 
(Watanabe et al. 2001). Thereby, this project is the first step towards a clinical 
diagnostic method using a real-time PCR assay, but further studies have to be 
done. However, it has to be investigated whether naturally infected cats shown 
positive with conventional nested RT-PCR also are positive with the new real-time 
PCR assay, as well as finding out which clinical samples contain most quantities of 
viral RNA and therefore would be the most suitable sample to take. 
 
 A new clinical diagnostic tool will not only be useful in diagnosing feline Borna 
disease, but also for epidemiological studies in search for the still unknown natural 
reservoir, as well as evaluating new relevant therapies. Screenings of the 
prevalence of BDV in different species will also be interesting. Considering the 
results of this study, real-time PCR assay will be a powerful tool for diagnosing 
Borna disease virus infections, not only in the living cat, but also in other species 
including man. 
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